

# GENEOSCOPY

*Revolutionizing Colorectal Cancer Screening*





**100 Million** Americans are recommended to undergo regular colorectal cancer (“CRC”) screening

However, only **58.2%** of Americans are compliant with preventative screening recommendations, resulting in unnecessarily high morbidity and mortality rates

**130,000+** patients are diagnosed with CRC annually

**50,000+** patients die from CRC annually




# Existing screening methodologies fail to address the needs of patients and providers

## Invasive Procedures

Colonoscopies have long been considered the “Gold Standard” of CRC screening, and are the primary method for diagnosing CRC. However, colonoscopies are problematic in several ways:

- Low Compliance Rates (fear of bowel preparation, invasiveness and time commitment)
- High Cost per Procedure



## Noninvasive Procedures


Noninvasive procedures (Cologuard, FIT tests, FOBT tests) alleviate some issues associated with colonoscopies, but are also highly problematic due to:

- Reduced Accuracy (low sensitivity rates and low specificity rates)
- Absence of a Therapeutic Procedure





# Geneoscopy's test solves the issues associated with existing screening procedures



## Geneoscopy's Test

Geneoscopy has created a series of novel techniques to isolate and preserve biomarkers in stool samples. Geneoscopy is using this method to identify a set of biomarkers associated with CRC and develop a screening test to diagnose the disease. The result is a test that combines the best features of existing methodologies:


- Noninvasive
- Low Cost
- Highly Accurate<sup>1</sup>
- Provides Additional Information (size, location and progression of the cancer)

In doing so, Geneoscopy is able to address and improve upon each aspect of the triple aim; improved patient experience, reduced cost and improved population health

<sup>1</sup> Preliminary validation indicates a sensitivity rate of 99% (Colonoscopy: 95%, Cologuard: 92%) and specificity rate of 95% (Colonoscopy: 95%, Cologuard: 87%)



# Geneoscopy 6-month timeline



Geneoscopy intends to apply Pennvention funds towards filing its utility patent and developing its customized stool collection kit




# Geneoscopy management team

## Executive Team



**Erica Barnell**  
MD/PhD candidate, WUSM  
*Chief Executive Officer*



**Andrew Barnell**  
MBA candidate, The Wharton School  
*Chief Financial Officer*



**Marianne Ligon**  
MD/PhD candidate, WUSM  
*Chief Operating Officer*



**Yiming Kang**  
PhD candidate, WUSTL  
*Chief Technology Officer*

## Advisory Board



**Michael S. Kinch, PhD**  
Director of Center for Research  
Innovation in Business, WUSTL



**Mark J. Manary, MD**  
Professor of Pediatrics, WUSM



**Nicholas O. Davidson, MD**  
Director of Gastroenterology, WUSM



**Harry Arader**  
Senior Entrepreneur Advisor